Here’s where the story ends – (TWST)

Fans of 80s/90s jangle pop might recall Harriet Wheeler and her band The Sundays singing about “that little souvenir of a terrible year”, fans of Silicon Valley corporate shenanigans should take note of this little souvenir,

ThumbDrive

as it plays a key role in the strange story of high flying Silicon Valley company Twist Biosciences (TWST).

Twist, which was founded in November 2011, or perhaps February 2012, or maybe February 2013, or possibly April 2013 (the corporate history is fluid at best), was an October 2018 IPO and currently sports a nearly $900mm valuation. The shares have been marching steadily higher over the last month, heading into the lockup expiration on the 29th of April. Investors must not have read the prospectus closely, or at all.

Much like bioturd Organovo (ONVO), Twist uses all sorts of biotech buzzwords (“oligonucleotides”, “synbio”, “synthetic DNA”, “NGS” and our favorite here at BuyersStrike! HQ “leverage e-commerce to scale the genomics business“) to hide what is really just an inkjet printer business. Yes, that is what Twist actually does. Fancy inkjets that print DNA. Instead of CMYK colored ink, the Twist machines spit out adenine (A), cytosine (C), guanine (G) and thymine (T) inks.

It is true that selling fancy ink for fancy inkjet printers can be a good business. Just ask Hewlett Packard (HPQ) and its spinout Agilent (A). Asking Agilent in particular about Twist, its founders, and its employees, would be very wise.

Let’s examine the history of Twist, some of its officers and learn about that little souvenir from an angry former employer…

(more…)

Advertisements

Quick Take – FDA delays Zogenix’s plan to poison children, sell side shill responds. (ZGNX)

Today after the bell, #fakeinnovation company Zogenix (ZGNX) announced that the FDA issued a “Refusal to File” letter for their recent NDA for “Fintepla“. This is absolutely the correct decision. Why?

Because Fintepla is not a new drug at all. It is #fakeinnovation. Fintepla is just a new brand name for a very dangerous drug that was taken off the market in 1997 for causing horrific heart valve problems in adults. That drug? Fenfluramine, aka Pondimin, aka the “Fen” in “Phen-Fen“.

Somehow the idiots at ZGNX thought 22 years later nobody would remember, and it would be a good idea to repurpose the drug and offer it to children. Guess not.

And the bigger idiots, of course, are the sycophantic sell side shills, like this moron, Danielle “Shill” Brill from Piper Jaffray.

ZGNXShill

After news like this she drops her price target from $72 all the way down to $68. As we say here at BuyersStrike! HQ, “hoes gots to eat too!”

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

 

 

 

Quick Take – When have you ever seen this? (THCT)

A company asking the SEC for permission to withdraw their registration statement, as it would not be in the public interest for investors to be able to purchase shares! Which leads to the question, what dark secret is the THC Therapeutics (THCT)Krim Krew trying to hide?

 

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

 

 

Quick Take – What’s in a name? (THCT)

Presenting just one aspect from the curious case of Vegas based, pink sheet stinker, THC Therapeutics (THCT), or is it Millenium Blockchain, or is it Millenial Weedscam? No matter what, it was, is and always will be a fairytale. As of today, the 5th of April 2019, a $220mm vape dream.

THCTNameChanges

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

 

 

A HAZY SHADE OF WINTER QUICK TAKE – PART 4 (TYME)

A few weeks ago we looked at the Tyme Technologies (TYME) “study “of their magic tyrosine cocktail, SM-88 (aka SMK, aka snake oil) in pancreatic cancer, catch up with that here.

Today, the jokers at TYME gave us all a little Valentine’s Day gift, interim “results” from their uncontrolled, open-label, tiny n, prostate cancer “study.”

One can find details on this terribly designed study, officially titled “Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer” here NCT02796898.

In today’s press release, the company declares: “TYME Reports Encouraging SM-88 Clinical Results”. In prostate cancer one easy metric is the patient’s PSA score. A declining PSA score is good. An increasing PSA score is bad. Says the company:

PSA levels generally remained stable during treatment.

That’s not actually encouraging at all. Now, here are the results that actually matter, from the poster.

TYME-PSA

Again “After 3 cycles of therapy (12 weeks), median PSA increased 40.2% from 6.4 to 9.0.” a 40% increase is NOT remaining stable.

FAIL.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.